{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:26:50Z","timestamp":1790832410875,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K08436"],"award-info":[{"award-number":["JP18K08436"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0410006"],"award-info":[{"award-number":["JP18fk0410006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0410006"],"award-info":[{"award-number":["JP18fk0410006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0410006"],"award-info":[{"award-number":["JP18fk0410006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["BC011109"],"award-info":[{"award-number":["BC011109"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CCR5 is a member of the G-protein coupled receptor family that serves as an essential co-receptor for cellular entry of R5-tropic HIV-1, and is a validated target for therapeutics against HIV-1 infections. In the present study, we designed and synthesized a series of novel small CCR5 inhibitors and evaluated their antiviral activity. GRL-117C inhibited the replication of wild-type R5-HIV-1 with a sub-nanomolar IC<jats:sub>50<\/jats:sub> value. These derivatives retained activity against vicriviroc-resistant HIV-1s, but did not show activity against maraviroc (MVC)-resistant HIV-1. Structural modeling indicated that the binding of compounds to CCR5 occurs in the hydrophobic cavity of CCR5 under the second extracellular loop, and amino acids critical for their binding were almost similar with those of MVC, which explains viral cross-resistance with MVC. On the other hand, one derivative, GRL-10018C, less potent against HIV-1, but more potent in inhibiting CC-chemokine binding, occupied the upper region of the binding cavity with its <jats:italic>bis<\/jats:italic>-THF moiety, presumably causing greater steric hindrance with CC-chemokines. Recent studies have shown additional unique features of certain CCR5 inhibitors such as immunomodulating properties and HIV-1 latency reversal properties, and thus, continuous efforts in developing new CCR5 inhibitors with unique binding profiles is necessary.<\/jats:p>","DOI":"10.1038\/s41598-019-41080-w","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T18:46:13Z","timestamp":1553021173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s"],"prefix":"10.1038","volume":"9","author":[{"given":"Hirotomo","family":"Nakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9424-1491","authenticated-orcid":false,"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-5888","authenticated-orcid":false,"given":"Debananda","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon B.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalapala Venkateswara","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyoshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"41080_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","volume":"3","author":"TJ Henrich","year":"2013","unstructured":"Henrich, T. J. & Kuritzkes, D. R. HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol 3, 51\u201357, https:\/\/doi.org\/10.1016\/j.coviro.2012.12.002 (2013).","journal-title":"Curr Opin Virol"},{"key":"41080_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1517\/14728214.2012.673584.","volume":"17","author":"K Maeda","year":"2012","unstructured":"Maeda, K., Das, D., Nakata, H. & Mitsuya, H. CCR5 inhibitors: emergence, success and challenges. Expert Opin Emerg Drugs 17, 135\u2013145, https:\/\/doi.org\/10.1517\/14728214.2012.673584. (2012).","journal-title":"Expert Opin Emerg Drugs"},{"key":"41080_CR3","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.2174\/1568026614666140827143745","volume":"14","author":"GG Xu","year":"2014","unstructured":"Xu, G. G., Guo, J. & Wu, Y. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications. Curr Top Med Chem 14, 1504\u20131514 (2014).","journal-title":"Curr Top Med Chem"},{"key":"41080_CR4","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1128\/AAC.01299-07","volume":"52","author":"H Nakata","year":"2008","unstructured":"Nakata, H. et al. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother 52, 2111\u20132119, https:\/\/doi.org\/10.1128\/AAC.01299-07 (2008).","journal-title":"Antimicrob Agents Chemother"},{"key":"41080_CR5","doi-asserted-by":"publisher","first-page":"e1005381","DOI":"10.1371\/journal.ppat.1005381","volume":"12","author":"S Serrano-Villar","year":"2016","unstructured":"Serrano-Villar, S. et al. Effects of combined CCR5\/integrase inhibitors-based regimen on mucosal immunity in HIV-infected patients na\u00efve to antiretroviral therapy: a pilot randomized trial. PLoS Pathog 12, e1005381, https:\/\/doi.org\/10.1371\/journal.ppat.1005381 (2016).","journal-title":"PLoS Pathog"},{"key":"41080_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1086\/650697","volume":"201","author":"DA Cooper","year":"2010","unstructured":"Cooper, D. A. et al. Maraviroc versus efavirenz, both in combination with zidovudine\u2013lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 201, 803\u2013813, https:\/\/doi.org\/10.1086\/650697 (2010).","journal-title":"J Infect Dis"},{"key":"41080_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1073\/pnas.01251909","volume":"99","author":"A Trkola","year":"2002","unstructured":"Trkola, A. et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 99, 395\u2013400, https:\/\/doi.org\/10.1073\/pnas.01251909 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"41080_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.virol.2005.04.035","volume":"338","author":"AJ Marozsan","year":"2005","unstructured":"Marozsan, A. J. et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338, 182\u2013199, https:\/\/doi.org\/10.1016\/j.virol.2005.04.035 (2005).","journal-title":"Virology"},{"key":"41080_CR9","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1128\/JVI.02006-06","volume":"81","author":"M Westby","year":"2007","unstructured":"Westby, M. et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81, 2359\u20132371, https:\/\/doi.org\/10.1128\/JVI.02006-06 (2007).","journal-title":"J Virol"},{"key":"41080_CR10","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1099\/vir.0.062885-0","volume":"95","author":"K Yoshimura","year":"2014","unstructured":"Yoshimura, K., Harada, S., Boonchawalit, S., Kawanami, Y. & Matsushita, S. Impact of maraviroc-resistant and low-CCR5-adapted mutation induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies. J Gen Virol 95, 1816\u20131826, https:\/\/doi.org\/10.1099\/vir.0.062885-0 (2014).","journal-title":"J Gen Virol"},{"key":"41080_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.virol.2006.11.004","volume":"361","author":"P Pugach","year":"2007","unstructured":"Pugach, P. et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361, 212\u2013228, https:\/\/doi.org\/10.1016\/j.virol.2006.11.004 (2007).","journal-title":"Virology"},{"key":"41080_CR12","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1021\/jm0509703","volume":"49","author":"M Seto","year":"2006","unstructured":"Seto, M. et al. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J Med Chem 49, 2037\u20132048, https:\/\/doi.org\/10.1021\/jm0509703 (2006).","journal-title":"J Med Chem"},{"key":"41080_CR13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","volume":"67","author":"O Krenkel","year":"2018","unstructured":"Krenkel, O. et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 67, 1270\u20131283, https:\/\/doi.org\/10.1002\/hep.29544 (2018).","journal-title":"Hepatology."},{"key":"41080_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/QAI.0b013e3181c5c83b","volume":"54","author":"DM Asmuth","year":"2010","unstructured":"Asmuth, D. M. et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 54, 394\u2013397, https:\/\/doi.org\/10.1097\/QAI.0b013e3181c5c83b (2010).","journal-title":"J Acquir Immune Defic Syndr"},{"key":"41080_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02634-y","volume":"7","author":"MR L\u00f3pez-Huertas","year":"2017","unstructured":"L\u00f3pez-Huertas, M. R. et al. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combinationwith the PKC-agonist Bryostatin-1. Sci Rep. 7, 2385, https:\/\/doi.org\/10.1038\/s41598-017-02634-y (2017).","journal-title":"Sci Rep."},{"key":"41080_CR16","doi-asserted-by":"publisher","first-page":"8654","DOI":"10.1128\/JVI.78.16.8654-8662.2004","volume":"78","author":"K Maeda","year":"2004","unstructured":"Maeda, K. et al. A spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine\/CCR5 interactions and exerts potent activity against R5 HIV-1 in vitro. J Virol 78, 8654\u20138662, https:\/\/doi.org\/10.1128\/JVI.78.16.8654-8662.2004 (2004).","journal-title":"J Virol"},{"key":"41080_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/01.aids.0000183633.06580.8a","volume":"19","author":"J Lalezari","year":"2005","unstructured":"Lalezari, J. et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 19, 1443\u20131448 (2005).","journal-title":"AIDS"},{"key":"41080_CR18","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1128\/JVI.74.4.1787-1793.2000","volume":"74","author":"Y Maeda","year":"2000","unstructured":"Maeda, Y., Foda, M., Matsushita, S. & Harada, S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J Virol 74, 1787\u20131793 (2000).","journal-title":"J Virol"},{"key":"41080_CR19","doi-asserted-by":"publisher","first-page":"35194","DOI":"10.1074\/jbc.M105670200","volume":"276","author":"K Maeda","year":"2001","unstructured":"Maeda, K. et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 276, 35194\u201335200, https:\/\/doi.org\/10.1074\/jbc.M105670200 (2001).","journal-title":"J Biol Chem"},{"key":"41080_CR20","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1084\/jem.20090365","volume":"206","author":"N Goonetilleke","year":"2009","unstructured":"Goonetilleke, N. et al. The first T cell response to transmitted\/founder virus contributes to the control of acute viremiain HIV-1 infection. J Exp Med. 206, 1253\u201372, https:\/\/doi.org\/10.1084\/jem.20090365 (2009).","journal-title":"J Exp Med."},{"key":"41080_CR21","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.1128\/JVI.00766-14","volume":"88","author":"R Shen","year":"2014","unstructured":"Shen, R. et al. Vaginal myeloid dendritic cells transmit founder HIV-1. J Virol. 88, 7683\u20138, https:\/\/doi.org\/10.1128\/JVI.00766-14 (2014).","journal-title":"J Virol."},{"key":"41080_CR22","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105, 7552\u20137557, https:\/\/doi.org\/10.1073\/pnas.0802203105 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41080_CR23","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1128\/JVI.02964-12","volume":"87","author":"ZF Parker","year":"2013","unstructured":"Parker, Z. F. et al. Transmitted\/founder and chronic HIV-1 envelope proteins are distinguished by differentialutilization of CCR5. J Virol. 87, 2401\u201311, https:\/\/doi.org\/10.1128\/JVI.02964-12 (2013).","journal-title":"J Virol."},{"key":"41080_CR24","doi-asserted-by":"publisher","first-page":"86:2715","DOI":"10.1128\/JVI.06157-11","volume":"2012","author":"C Ochsenbauer","year":"2011","unstructured":"Ochsenbauer, C. et al. Generation of transmitted\/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol. 2012, 86:2715\u201328, https:\/\/doi.org\/10.1128\/JVI.06157-11 (2011).","journal-title":"J Virol."},{"key":"41080_CR25","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.1241475","volume":"341","author":"Q Tan","year":"2013","unstructured":"Tan, Q. et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387\u20131390, https:\/\/doi.org\/10.1126\/science.1241475 (2013).","journal-title":"Science"},{"key":"41080_CR26","doi-asserted-by":"publisher","first-page":"12688","DOI":"10.1074\/jbc.M512688200","volume":"281","author":"K Maeda","year":"2006","unstructured":"Maeda, K. et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem. 281, 12688\u201312698, https:\/\/doi.org\/10.1074\/jbc.M512688200 (2006).","journal-title":"J Biol Chem."},{"key":"41080_CR27","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jmb.2008.06.041","volume":"381","author":"K Maeda","year":"2008","unstructured":"Maeda, K. et al. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: Insights to mechanism of allosteric inhibition. J. Mol. Biol. 381, 956\u2013974, https:\/\/doi.org\/10.1016\/j.jmb.2008.06.041 (2008).","journal-title":"J. Mol. Biol."},{"key":"41080_CR28","doi-asserted-by":"publisher","first-page":"e1000548","DOI":"10.1371\/journal.ppat.1000548","volume":"5","author":"R Berro","year":"2009","unstructured":"Berro, R. et al. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 5, e1000548, https:\/\/doi.org\/10.1371\/journal.ppat.1000548 (2009).","journal-title":"PLoS Pathog"},{"key":"41080_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/QAD.0000000000001043","volume":"30","author":"C Herrera","year":"2016","unstructured":"Herrera, C. et al. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposureprophylaxis candidates. AIDS. 30, 1015\u201325, https:\/\/doi.org\/10.1097\/QAD.0000000000001043 (2016).","journal-title":"AIDS."},{"key":"41080_CR30","doi-asserted-by":"publisher","unstructured":"Brocca-Cofano, E. et al. Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques. J Virol. 92, https:\/\/doi.org\/10.1128\/JVI.00576-18 (2018).","DOI":"10.1128\/JVI.00576-18"},{"key":"41080_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/infdis\/jiw525","volume":"215","author":"RM Gulick","year":"2017","unstructured":"Gulick, R. M. et al. Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069\/ACTG A5305). J Infect Dis. 215, 238\u2013246, https:\/\/doi.org\/10.1093\/infdis\/jiw525 (2017).","journal-title":"J Infect Dis."},{"key":"41080_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/QAD.0000000000000988","volume":"30","author":"M Thompson","year":"2016","unstructured":"Thompson, M. et al. A 48-week randomized Phase 2b study evaluating cenicriviroc vs. efavirenz in treatment-na\u00efve HIV-infected adults with CCR5-tropic virus. AIDS 30, 869\u2013878, https:\/\/doi.org\/10.1097\/QAD.0000000000000988 (2016).","journal-title":"AIDS"},{"key":"41080_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.bmcl.2006.10.084","volume":"17","author":"R Nishizawa","year":"2007","unstructured":"Nishizawa, R. et al. Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite. Bioorg Med Chem Lett 17, 727\u2013731, https:\/\/doi.org\/10.1016\/j.bmcl.2006.10.084 (2007).","journal-title":"Bioorg Med Chem Lett"},{"key":"41080_CR34","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49, 4721\u20134732, https:\/\/doi.org\/10.1128\/AAC.49.11.4721-4732.2005 (2005).","journal-title":"Antimicrob Agents Chemother"},{"key":"41080_CR35","doi-asserted-by":"crossref","unstructured":"Baba, M. et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA. 96, 5698\u20135703 (1999).","DOI":"10.1073\/pnas.96.10.5698"},{"key":"41080_CR36","doi-asserted-by":"publisher","first-page":"12718","DOI":"10.1073\/pnas.221375398","volume":"98","author":"JM Strizki","year":"2001","unstructured":"Strizki, J. M. et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 98, 12718\u201312723, https:\/\/doi.org\/10.1073\/pnas.221375398 (2001).","journal-title":"Proc Natl Acad Sci USA"},{"key":"41080_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1126\/science.3014648","volume":"233","author":"S Gartner","year":"1986","unstructured":"Gartner, S. et al. The role of mononuclear phagocytes in HTLV-III\/LAV infection. Science 233, 215\u2013219 (1986).","journal-title":"Science"},{"issue":"11","key":"41080_CR38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/cmdc.201500590","volume":"2016","author":"N Ohashi","year":"2016","unstructured":"Ohashi, N. et al. Small-molecule CD4 mimics containing mono-cyclohexyl moieties as HIV entry inhibitors. Chem Med Chem 2016(11), 940\u2013946, https:\/\/doi.org\/10.1002\/cmdc.201500590 (2016).","journal-title":"Chem Med Chem"},{"key":"41080_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3851\/IMP1529","volume":"15","author":"H Nakata","year":"2010","unstructured":"Nakata, H. et al. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions. Antivir Ther 15, 321\u2013331, https:\/\/doi.org\/10.3851\/IMP1529 (2010).","journal-title":"Antivir Ther"},{"key":"41080_CR40","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1128\/AAC.04654-14","volume":"59","author":"D Das","year":"2015","unstructured":"Das, D. et al. Insights into the mechanism of inhibition of CXCR4: identification of piperidinylethanamine analogs as anti-HIV-1 inhibitors. Antimicrob Agents Chemother 59, 1895\u20131904, https:\/\/doi.org\/10.1128\/AAC.04654-14 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"41080_CR41","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47, 1739\u20131749, https:\/\/doi.org\/10.1021\/jm0306430 (2004).","journal-title":"J Med Chem"},{"key":"41080_CR42","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner, R. A. et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49, 6177\u20136196, https:\/\/doi.org\/10.1021\/jm051256o (2006).","journal-title":"J Med Chem"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41080-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41080-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41080-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:47:10Z","timestamp":1671263230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41080-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41080"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41080-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"24 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4828"}}